

## CONTENTS

### Editorial

- 7789 **Radioimmunotherapy for Non-Hodgkin's Lymphoma.** Jonathan W. Friedberg.

### Featured Articles

#### Clinical Trials

- 7792 **The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy.** Thomas A. Davis, Mark S. Kaminski, John P. Leonard, Frank J. Hsu, Mary Wilkinson, Andrew Zelenetz, Richard L. Wahl, Stewart Kroll, Morton Coleman, Michael Goris, Ronald Levy, and Susan J. Knox.
- 7799 **Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens.** Scott S. Tykodi, Edus H. Warren, John A. Thompson, Stanley R. Riddell, Richard W. Childs, Brith E. Otterud, Mark F. Leppert, Rainer Storb, and Brenda M. Sandmaier.
- 7812 **A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma.** Nancy A. Dawson, Chuanfo Guo, Richard Zak, Brenda Dorsey, Jeanne Smoot, Jade Wong, and Arif Hussain.

#### Molecular Oncology, Markers, Clinical Correlates

- 7820 **Molecular Stratification of Diagnostically Challenging High-Grade Gliomas Composed of Small Cells: The Utility of Fluorescence *In situ* Hybridization.** Andrey Korshunov, Regina Sycheva, and Andrey Golanov.
- 7827 **Clinical Significance of Micrometastatic Cells Detected by E48 (Ly-6D) Reverse Transcription-Polymerase Chain Reaction in Bone Marrow of Head and Neck Cancer Patients.** David R. Colnot, Eline J. C. Nieuwenhuis, Dirk J. Kuik, C. René Leemans, Janny Dijkstra, Gordon B. Snow, Guus A. M. S. van Dongen, and Ruud H. Brakenhoff.

#### Experimental Therapeutics, Preclinical Pharmacology

- 7834 **Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease.** Diane E. Milenic, Kayhan Garmestani, Erik D. Brady, Paul S. Albert, Dangshe Ma, Alia Abdulla, and Martin W. Brechbiel.
- 7842 **Efficient Elimination of B-Lineage Lymphomas by Anti-CD20-Auristatin Conjugates.** Che-Leung Law, Charles G. Cerveney, Kristine A. Gordon, Kerry Klussman, Bruce J. Mixan, Dana F. Chace, Damon L. Meyer, Svetlana O. Doronina, Clay B. Siegall, Joseph A. Francisco, Peter D. Senter, and Alan F. Wahl.

- 7852 **Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker.** Daniel E. Hall, Bradford A. Moffat, Jadranka Stojanovska, Timothy D. Johnson, Zhuolin Li, Daniel A. Hamstra, Alnawaz Rehemtulla, Thomas L. Chenevert, Julie Carter, Dennis Pietronigro, and Brian D. Ross.

### Regular Articles

#### Clinical Trials

- 7860 **S-1 Plus Cisplatin Combination Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Multi-Institutional Phase II Trial.** Yukito Ichinose, Kozo Yoshimori, Hiroshi Sakai, Yushi Nakai, Takahiko Sugiura, Masaaki Kawahara, and Hisanobu Niitani.

#### Molecular Oncology, Markers, Clinical Correlates

- 7865 **Proteinase Activity in Human and Murine Saliva as a Biomarker for Proteinase Inhibitor Efficacy.** Barbara Fingleton, Ramkumar Menon, Kathy J. Carter, P. Dawn Overstreet, David L. Hachey, Lynn M. Matrisian, and J. Oliver McIntyre.
- 7875 **Apurinic Endonuclease Activity in Adult Gliomas and Time to Tumor Progression After Alkylating Agent-Based Chemotherapy and After Radiotherapy.** Michael S. Bobola, Mary J. Emond, A. Blank, Elizabeth H. Meade, Douglas D. Kolstoe, Mitchel S. Berger, Robert C. Rostomily, Daniel L. Silbergeld, Alexander M. Spence, and John R. Silber.
- 7884 **Partial Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/TRAIL Receptor Pathway to Antitumor Effects of Interferon- $\alpha$ /5-Fluorouracil against Hepatocellular Carcinoma.** Tameyoshi Yamamoto, Hiroaki Nagano, Masato Sakon, Hisashi Wada, Hidetoshi Eguchi, Motoi Kondo, Bazarragchaa Damdinsuren, Hideo Ota, Masato Nakamura, Hiroshi Wada, Shigeru Marubashi, Atsushi Miyamoto, Keizo Dono, Koji Umeshita, Shoji Nakamori, Hideo Yagita, and Morito Monden.
- 7896 **Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias.** Zineb Benderra, Anne-Marie Faussat, Lydia Sayada, Jean-Yves Perrot, Driss Chaoui, Jean-Pierre Marie, and Ollivier Legrand.
- 7903 **Thymidylate Synthase 5'- and 3'-Untranslated Region Polymorphisms Associated with Risk and Progression of Squamous Cell Carcinoma of the Head and Neck.** Zhengdong Zhang, Qiuling Shi, Erich M. Sturgis, Margaret R. Spitz, Waun Ki Hong, and Qingyi Wei.
- 7911 **Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy: No *In vivo* Effect of Fas Ligand Tumor Counterattack.** Frede Donskov, Hans von der Maase, Niels Marcussen, Stephen Hamilton-Dutoit, Hans Henrik Torp Madsen, Jens Jorgen Jensen, and Marianne Hokland.

- 7917** **Hypermethylation of the GATA Genes in Lung Cancer.** Mingzhou Guo, Yoshimitsu Akiyama, Michael G. House, Craig M. Hooker, Elizabeth Heath, Edward Gabrielson, Stephen C. Yang, Yu Han, Stephen B. Baylin, James G. Herman, and Malcolm V. Brock.
- 7925** **Carbonic Anhydrase IX in Early-Stage Non-Small Cell Lung Cancer.** Seok Jin Kim, Zahid N. Rabbani, Robin T. Vollmer, Ernst-Gilbert Schreiber, Egbert Oosterwijk, Mark W. Dewhirst, Zeljko Vujaskovic, and Michael J. Kelley.
- 7934** **Plasma Glutathione S-Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin's Lymphoma (Stages III and IV).** Tatsuro Katahira, Tetsuji Takayama, Koji Miyanishi, Tsuyoshi Hayashi, Tatsuru Ikeda, Yasuo Takahashi, Rishu Takimoto, Takuya Matsunaga, Junji Kato, and Yoshiro Niitsu.
- 7941** **Preradiotherapy Hemoglobin Level but not Microvessel Density Predicts Locoregional Control and Survival in Laryngeal Cancer Treated with Primary Radical Radiotherapy.** Hedda Haugen, Bengt Magnusson, Marie Svensson, and Claes Mercke.
- 7950** **Interplay of Insulin-Like Growth Factor-II, Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-I Receptor, COX-2, and Matrix Metalloproteinase-7 Play Key Roles in the Early Stage of Colorectal Carcinogenesis.** Katsuhiko Noshu, Hiroyuki Yamamoto, Hiroaki Taniguchi, Yasushi Adachi, Yukinari Yoshida, Yoshiaki Arimura, Takao Endo, Yuji Hinoda, and Kohzoh Imai.
- 7958** **Gain of OGP, an Estrogen-Regulated Oviduct-Specific Glycoprotein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer.** Michelle M. Woo, Abdulmohsen Alkushi, Harold G. Verhage, Anthony M. Magliocco, Peter C. K. Leung, C. Blake Gilks, and Nelly Auersperg.
- 7965** **Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification.** Ilse Van der Auwera, Steven J. Van Laere, Gert G. Van den Eynden, Ina Benoy, Peter van Dam, Cecile G. Colpaert, Stephen B. Fox, Helen Turley, Adrian L. Harris, Eric A. Van Marck, Peter B. Vermeulen, and Luc Y. Dirix.
- 7972** **c-erbB-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1 $\alpha$  Dependent.** Alexandra Giatromanolaki, Michael I. Koukourakis, Costantinos Simopoulos, Alexandros Polychronidis, Kevin C. Gatter, Adrian L. Harris, and Efthimios Sivridis.
- 7978** **Detection of Neuroblastoma Cells in Bone Marrow and Peripheral Blood by Different Techniques: Accuracy and Relationship with Clinical Features of Patients.** Maria Valeria Corrias, Lawrence B. Faulkner, Angela Pistorio, Cristina Rosanda, Francesco Callea, Maria Serena Lo Piccolo, Paola Scaruffi, Cinzia Marchi, Laura Lacitignola, Marzia Occhino, Claudio Gambini, Gian Paolo Tonini, Riccardo Haupt, Bruno De Bernardi, Vito Pistoia, and Alberto Garaventa.
- 7986** **Lack of Impact of the Loss of Constitutive Folate Receptor  $\alpha$  Expression, Achieved by RNA Interference, on the Activity of the New Generation Antifolate Pemetrexed in HeLa Cells.** Shrikanta Chattopadhyay, Yanhua Wang, Rongbao Zhao, and I. David Goldman.
- 7994** **Evaluation of Combination Chemotherapy: Integration of Nonlinear Regression, Curve Shift, Isobologram, and Combination Index Analyses.** Liang Zhao, M. Guillaume Wientjes, and Jessie L-S. Au.
- 8005** **Lack of Microvessels in Well-Differentiated Regions of Human Head and Neck Squamous Cell Carcinoma A253 Associated with Functional Magnetic Resonance Imaging Detectable Hypoxia, Limited Drug Delivery, and Resistance to Irinotecan Therapy.** Arup Bhattacharya, Károly Tóth, Richard Mazurchuk, Joseph A. Sperryak, Harry K. Slocum, Lakshmi Pendyala, Rami Azrak, Shousong Cao, Farukh A. Durrani, and Youcef M. Rustum.
- 8018** **Inhibition of Proliferation and Induction of Apoptosis by 25-Hydroxyvitamin D<sub>3</sub>-3 $\beta$ -(2)-Bromoacetate, a Nontoxic and Vitamin D Receptor-Alkylating Analog of 25-Hydroxyvitamin D<sub>3</sub> in Prostate Cancer Cells.** Narasimha Swamy, Tai C. Chen, Sara Peleg, Puneet Dhawan, Sylvia Christakos, LaMonica V. Stewart, Nancy L. Weigel, Rajendra G. Mehta, Michael F. Holick, and Rahul Ray.
- 8028** **Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice.** Maksim V. Yezhelyev, Gudrun Koehl, Markus Guba, Thomas Brabletz, Karl-Walter Jauch, Anderson Ryan, Alan Barge, Tim Green, Michael Fennell, and Christiane J. Bruns.
- 8037** **Inhibition of Cyclooxygenase (COX)-2 Expression by Tet-Inducible COX-2 Antisense cDNA in Hormone-Refractory Prostate Cancer Significantly Slows Tumor Growth and Improves Efficacy of Chemotherapeutic Drugs.** Devendra S. Dandekar and Bal L. Lokeshwar.
- 8048** **Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors.** James M. Gallo, Paolo Vicini, Amy Orlansky, Shaolan Li, Feng Zhou, Jianguo Ma, Sharon Pulfer, Michel A. Bookman, and Ping Guo.
- 8059** **Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity.** Linda A. deGraffenried, William E. Friedrichs, Douglas H. Russell, Elissa J. Donzis, Amanda K. Middleton, Jessica M. Silva, Richard A. Roth, and Manuel Hidalgo.
- 8068** **Prognostic Significance of Tissue Transglutaminase in Drug Resistant and Metastatic Breast Cancer.** Kapil Mehta, Jansina Fok, Fred R. Miller, Dimpy Koul, and Aysegul A. Sahin.
- 8077** **Enhanced Tumor Cell Radiosensitivity and Abrogation of G<sub>2</sub> and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin.** Elizabeth E. A. Bull, Hideaki Dote, Kristin J. Brady, William E. Burgan, Donna J. Carter, Michael A. Cerra, Kelli A. Oswald, Melinda G. Hollingshead, Kevin Camphausen, and Philip J. Tofilon.
- 8085** **pRb2/p130 Decreases Sensitivity to Apoptosis Induced by Camptothecin and Doxorubicin but not by Taxol.** Tiziana Tonini, Chiara Gabellini, Luigi Bagella, Giuseppina D'Andrilli, Valeria Masciullo, Gaetano Romano, Giovanni Scambia, Gabriella Zupi, and Antonio Giordano.
- 8094** **Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor  $\alpha$ -Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines.** John Patrick Alao, Eric W-F. Lam, Simak Ali, Laki Buluwela, Walter Bordogna, Peter Lockey, Rana Varshochi, Alexandra V. Stavropoulou, R. Charles Coombes, and David M. Vigushin.

## Experimental Therapeutics, Preclinical Pharmacology

**8105 The Selective Cyclooxygenase-2 Inhibitor Nimesulide Prevents *Helicobacter pylori*-Associated Gastric Cancer Development in a Mouse Model.** Ki Taek Nam, Ki-Baik Hahm, Sang-Yeon Oh, Marie Yeo, Sang-Uk Han, Byeongwoo Ahn, Young-Bae Kim, Jin Seok Kang, Dong Deuk Jang, Ki-Hwa Yang, and Dae-Yong Kim.

Cancer Biology

**8114 Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells.** Elizabeth A. Lafleur, Nadezhda V. Koshkina, John Stewart, Shu-Fang Jia, Laura L. Worth, Xiaoping Duan, and Eugenie S. Kleinerman.

**8120 Natural Killer Cells Activity and Neuroimmunological Treatment of Cancer.** Fuad Lechin, Bertha van der Dijs, and Alex E. Lechin.

**8120 In Response.** Gabriele Multhoff, Karin Pfister, Ilona Hromadnikova, and Denisa Zlacka.

---

**8122 Acknowledgment to Reviewers**

**i Instructions for Authors**

---

**The Cover**

**Internalization of an anti-CD20 antibody drug-conjugate via clathrin-coated vesicles.** Ramos B cells incubated with the conjugate rituximab-vcMMAE were fixed, permeabilized, and cell-associated rituximab-vcMMAE was detected using Alexa Fluor-568 conjugated mouse anti-human IgG (H+L) (red). Clathrin-coated vesicles were detected by a mouse antibody raised against clathrin heavy chain followed by

an Alexa Fluor-488 conjugated goat anti-mouse IgG (H+L) antibody with minimal cross-reactivity to human IgG (green). Cell nuclei were counterstained with 4', 6-Diamidino-2-phenylindole (Blue). Co-localization of rituximab-vcMMAE to clathrin-coated vesicles is represented by yellow signals. For further details see Law *et al.*, on page 7842 in this issue.

---